The overall program investigates the importance of muscle mass and function for healthy ageing. Loss of muscle mass and strength is an independent risk factor for morbidity and mortality in a range of diseases, such as diabetes and cancer, and of course ageing.
The Australian Institute for Musculoskeletal Science (AIMSS) is a collaborative institute for translational research into ageing and musculoskeletal diseases.
AIMSS brings clinicians, epidemiologists and biomedical researchers together from Western Health, Victoria University and The University of Melbourne to bring researchers closer to the health system and to better influence healthcare delivery based on research.
We aim to improve the health and wellbeing of the communities in which we live and work through innovative and integrative musculoskeletal research and advocacy. Our mission is to undertake focused, high quality, innovative research; foster collaborations with the research and general community; and promote healthy and active living in the communities we serve.
AIMSS is leading the way in basic, translational and clinical research, and providing an environment that is cohesive, inclusive and inspiring to attract and retain a high-calibre workforce. We are continually developing interactions between clinicians, researchers and the community to promote healthy ageing and to improve the understanding, treatment and prevention of musculoskeletal disease.
AIMSS has multiple ongoing collaborations with research institutes in Australia and around the world. Our strong network of collaborations allows us to have a major impact on musculoskeletal research worldwide.
AIMSS conducts internationally recognised high-quality clinical trials looking into disorders of bone, muscle and joint. The purpose of each clinical trial is to investigate scientific questions and attempts to find better ways to prevent, screen, diagnose and treat a disease.
Our trial portfolio includes both investigator initiated and sponsored clinical trials conducted according to Australian and International guidelines for medical research under the approval of a Human Research Ethics Committee (HREC).
Our purpose is to provide patients the opportunity to contribute to ongoing research and to ensure that patients receive the most up to date care from health professionals.
To find out how you can be part of our clinical trials please contact our Clinical Trial Coordinator (03) 8395 8233 or click below to fill in an online form.
Latest News & Events
Led by Natalie Sims, this program identifies new pathways for treatment of bone disease by studying intercellular communication within the bone microenvironment, particularly the communication between osteoblasts (bone forming cells) and osteoclasts (bone resorbing cells).
Therapies that are used to treat many cancers can negatively impact upon the musculoskeletal system such as loss of bone density (osteoporosis) and increased fracture risk, joint pain and stiffness, bone pain, muscle pain and muscle weakness all adding to a poor quality of life for the cancer patient.